Interesting to think where we will be 1 year from today. Not only is it plausible that revs could very well come in around $27-29 million for all of 2017 (if Fluticare gets approved soon) but with profitability, o/s could only be 130-135M then. NOT BAD
(1)
(0)
Innovus Pharmaceuticals Inc. (INNV) Stock Research Links